Lerisha-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction and mucus production, providing additional relief in allergic airway diseases. The synergistic action of these agents offers comprehensive control of allergic symptoms by targeting different inflammatory pathways. Lerisha-M is typically prescribed for patients who require both antihistaminic and leukotriene receptor antagonist therapy to achieve optimal symptom control. It is well tolerated with a low incidence of adverse effects; common side effects may include headache, fatigue, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment or a history of neuropsychiatric events. Lerisha-M should be used under medical supervision, with dosage adjustments as necessary based on clinical response. This combination therapy enhances patient compliance by simplifying treatment regimens for allergic disorders.